Skip to content
DataLookout
Menu

NCT04416178

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

StatusRecruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 20 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Study completion pushed from Dec 2026 to May 2027
    • Study description revised
    • Site details revised
  2. Minor Site contact updatedv19
  3. Notable Eligibility criteria expanded, about 54 words
    • Trial arms changed: 2 → 3
    v18
  4. Notable Trial status: Active, Not Recruiting to Recruitingv17 Show 5 more changesShow less
    • Eligibility criteria expanded, about 63 words
    • Enrollment target: 300 to 352
    • Study completion date: Dec 2025 to Dec 2026
    • Study description expanded, about 23 words
    • Site details revised
  5. Minor Trial status: Completed to Active, Not Recruiting
    • Study completion date: Mar 26, 2024 to Dec 2025
    • Study description expanded, about 24 words
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. Minor Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Jun 2024 to Mar 26, 2024
    v15
  2. Minor Primary and study completion dates: Feb 2024 to Jun 2024v14
  3. Minor Primary and study completion dates: Sep 2023 to Feb 2024v13
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v12
  5. Notable Primary and study completion dates: Sep 2022 to Sep 2023v11
  6. Minor Enrollment target: 312 to 300
    • Study description shortened, about 47 words
    v10
  7. Minor Start date changed from estimate of Jan 2021 to Dec 17, 2020v9
  8. Notable Trial status: Suspended to Recruitingv8 Show 6 more changesShow less
    • Primary and study completion dates pushed to Sep 2022
    • Start date: Nov 2020 to Jan 2021
    • Enrollment target: 300 to 312
    • Study description expanded, about 71 words
    • Site details revised
    • Study title revised
  9. Minor Start date: Oct 2020 to Nov 2020v7
  10. Minor Start date: Sep 2020 to Oct 2020v6
  11. Minor Start date: Aug 2020 to Sep 2020v5
  12. Minor Start date: Jul 2020 to Aug 2020v4
  13. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Temporary Enrollment Hold due to COVID-19
    • Start date: Jun 2020 to Jul 2020
    • Site details revised
    v3
  14. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Use of semi-structured interviews in parents of SCD patients to qualitatively describe parental attitudes of research involving genomic sequencing, including concerns about participation and expectations from researchers
Timeframe: Day 1, or at a future visit (up to approximately 1 year)
Use of surveys to quantitatively measure genetic/genomic knowledge, trust in health care provider/researchers, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD.
Timeframe: Day 1

Arms and interventions

Survey and Interview Group (Group1)

Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13-18 with aforementioned SCD genotype.

Focus Group (Group 2)

Adult Patient with or Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 16-18 with aforementioned SCD genotype whose parent provides verbal informed consent for focus group participation.

Usability and Pilot Testing (Group 3)

Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13 and up with aforementioned SCD genotype.

Sites

1 site in 1 country

  • St. Jude Children's Research HospitalMemphis, Tennessee, United States